Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT06924983

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Yong Jiang (from the registry)
Registry
  • NCT NCT06924983
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06924983. Randomized; triple masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage
Acronym
NEMP-BGH
Condition
Stroke
Condition
Intracerebral Hemorrhage Basal Ganglia
Condition
Methylprednisolone
Condition
Surgery
Intervention (Procedure)
Simple neuroendoscopic hematoma evacuation
Intervention (Combination product)
Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
Lead sponsor
Yong Jiang (class: other)

Record details

Record id
cardio:ct-nct06924983
Content hash
078cd97f2032f027e5d7dccc680c71738ae895f96dd11a08e298e08f335f2ba5